News Release: Schering Group - Sixteen-Year Follow-up Study Reinforces Betaferon Long-Term Efficacy, Safety and Tolerability in MS: "San Diego, USA, April 4, 2006..Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that Betaferon (interferon beta 1b) remained consistently safe, effective and well tolerated over the long term, according to results of the Betaferon 16-Year Long-Term Follow-up (16-Year LTF) Study presented at the 58th Annual Meeting of the American Academy of Neurology. This is the longest follow-up study for any disease modifying therapy in MS..."